Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3152555 | 0.91 | F10 (0.53) | F10KCNH2 | |
| SCHEMBL3161242 | 0.91 | F10 (0.48) | F10KCNH2NR3C1 | |
| SCHEMBL3160792 | 0.90 | F10 (0.49) | F10KCNH2NR3C1 | |
| SCHEMBL3900811 | 0.90 | F10 (0.44) | F10KCNH2NR3C1TP53MAPT | |
| SCHEMBL3905620 | 0.90 | F10 (0.43) | F10KCNH2NR3C1TP53MAPT | |
| SCHEMBL3156227 | 0.89 | F10 (0.47) | F10KCNH2MAPT | |
| SCHEMBL13902793 | 0.89 | F10 (0.39) | F10KCNH2NR3C1TP53MAPT | |
| SCHEMBL3907007 | 0.87 | TOP2A (0.46) | TP53MAPTTOP2A | |
| SCHEMBL8286967 | 0.86 | F10 (0.48) | F10 | |
| SCHEMBL3160681 | 0.86 | F10 (0.48) | F10NR3C1TP53MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511066-B2 | Antithrombotic aromatic ethers | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511066-B2 | Antithrombotic aromatic ethers | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070027185-A1 | Antithrombotic aromatic ethers | ELILILLY AND COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027185-A1 | Antithrombotic aromatic ethers | ELILILLY AND COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027185-A1 | Antithrombotic aromatic ethers | ELILILLY AND COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| EP-1670783-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005049604-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049604-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027185-A1 | Antithrombotic aromatic ethers | F2, F11, TFPI | F10 14/4885KCNH2 1280/4885NR3C1 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.